Literature DB >> 29182762

Cognitive Function Among Antiretroviral Treatment-Naive Individuals Infected With Human Immunodeficiency Virus Type 1 Subtype G Versus CRF02_AG in Nigeria.

Jibreel Jumare1, Nicaise Ndembi1, Samer S El-Kamary1, Laurence Magder1, Laura Hungerford1, Tricia Burdo2, Lindsay M Eyzaguirre1, Patrick Dakum1, Anya Umlauf3, Mariana Cherner3, Alash'le Abimiku1, Man Charurat1, William A Blattner1, Walter Royal1.   

Abstract

Background: Human immunodeficiency virus type 1 (HIV-1) subtype has been shown to be associated with disease progression. We compared cognitive function between individuals infected with HIV-1 subtype G and CRF02_AG in Nigeria.
Methods: For this cross-sectional study, samples were analyzed from 146 antiretroviral-naive participants. Genotypic analysis of plasma HIV RNA was performed by nested polymerase chain reaction of protease and reverse transcriptase genes, and sequences were aligned with curated HIV-1 subtype references. Cognitive status was determined using demographically adjusted T scores and global deficit score (GDS) obtained from a comprehensive neuropsychological test battery.
Results: A total of 76 (52.1%) participants were infected with CRF02_AG, 48 (32.8%) with subtype G, and 22 (15.1%) with other HIV-1 strains. In a multivariable linear regression adjusting for plasma HIV RNA, CD4 count, and depression score, mean global T score was lower among subtype G-infected compared with CRF02_AG-infected participants (mean difference, -3.0 [95% confidence interval {CI}, -5.2, to -.7]; P = .011). Also, T scores were significantly lower among subtype G- than CRF02_AG-infected participants for the speed of information processing, executive function, and verbal fluency ability domains. Adjusting for similar variables in a logistic regression, the odds of global cognitive impairment (GDS ≥0.5) were 2.2 times higher among subtype G compared with CRF02_AG-infected participants (odds ratio, 2.2 [95% CI, .9-5.4]; P = .078). Conclusions: Cognitive performance was significantly worse among antiretroviral-naive individuals with HIV-1 subtype G vs CRF02_AG infection. Further studies are required to characterize the mechanistic basis for these differences.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29182762      PMCID: PMC5905588          DOI: 10.1093/cid/cix1019

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  39 in total

1.  Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.

Authors:  Philippa J Easterbrook; Mel Smith; Jane Mullen; Siobhan O'Shea; Ian Chrystie; Annemiek de Ruiter; Iain D Tatt; Anna Maria Geretti; Mark Zuckerman
Journal:  J Int AIDS Soc       Date:  2010-02-03       Impact factor: 5.396

2.  FastTree 2--approximately maximum-likelihood trees for large alignments.

Authors:  Morgan N Price; Paramvir S Dehal; Adam P Arkin
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

3.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

4.  Functional complementation of the envelope hypervariable V3 loop of human immunodeficiency virus type 1 subtype B by the subtype E V3 loop.

Authors:  H Sato; K Kato; Y Takebe
Journal:  Virology       Date:  1999-05-10       Impact factor: 3.616

Review 5.  The neuropathogenesis of AIDS.

Authors:  Francisco González-Scarano; Julio Martín-García
Journal:  Nat Rev Immunol       Date:  2005-01       Impact factor: 53.106

6.  Differential effects of Tat proteins derived from HIV-1 subtypes B and recombinant CRF02_AG on human brain microvascular endothelial cells: implications for blood-brain barrier dysfunction.

Authors:  Shawna M Woollard; Biju Bhargavan; Fang Yu; Georgette D Kanmogne
Journal:  J Cereb Blood Flow Metab       Date:  2014-03-26       Impact factor: 6.200

7.  MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection.

Authors:  A Karlsson; K Parsmyr; E Sandström; E M Fenyö; J Albert
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

8.  A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals.

Authors:  Thomas D Marcotte; Reena Deutsch; Benedict Daniel Michael; Donald Franklin; Debra Rosario Cookson; Ajay R Bharti; Igor Grant; Scott L Letendre
Journal:  J Neuroimmune Pharmacol       Date:  2013-10-08       Impact factor: 4.147

Review 9.  Cognitive neuropsychology of HIV-associated neurocognitive disorders.

Authors:  Steven Paul Woods; David J Moore; Erica Weber; Igor Grant
Journal:  Neuropsychol Rev       Date:  2009-05-22       Impact factor: 7.444

Review 10.  Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND).

Authors:  Vasudev R Rao; Arthur P Ruiz; Vinayaka R Prasad
Journal:  AIDS Res Ther       Date:  2014-05-19       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.